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With the rapid increase in therapeutic options for patients 
with moderate or severe psoriasis in recent years, the primary 
therapeutic aim is no longer an improvement of symptoms, 
but rather their complete elimination. Corresponding to a 
reduction of the PASI by more than 75 % (PASI75),  thus ma-
king it possible for patients to participate in professional life 
and taking a more active role in public life. As a consequence, 
also their amount of travelling increases. Limitations in mo-
bility and representation are no longer based on appearance 
and symptoms of the inflammatory skin disorder, but on the 
medication needed, which in turn requires certain conditions 
and a particular handling, such as regular doctor‘s visits and 
laboratory controls. The marked increase in prescriptions 
of biologics in recent years together with the high German 
travel activity, implies a steady increase in the number of af-
fected travelers [1, 2]. Especially for travelling, an attending 
physician has several aspects to consider. Therefore, we 
would like to provide practical advice on therapy planning 
for travelers, also taking into account currently available sys-
temic therapies for psoriasis.
Travel situations
Travelling is associated with a variety of factors concerning 
duration, destination, and motive which have to be taken into 
account by the physician before initiating a systemic therapy.
Working patients with travel activities need medication 
that is easy to transport and does not require complex applica-
tion, frequent laboratory controls or short intervals between 
doctor’s visits. Understandingly, patients want to be flexible 
with short business trips over a few days or with compulsory 
appointments, especially at short notice. In case of interna-
tional travelling, the transport of drugs in airplanes, as well 
as transfer times need to be considered. Obligatory customs 
declaration forms should be kept in mind, too. According 
to German law, it is permitted to carry drugs in adequate 
amounts for personal use. Exceptions are prohibited substan-
ces, such as doping substances or counterfeit drugs. Special 
guidelines must be observed for narcotics [3, 4]. Current in-
formation for the country of destination must be obtained 
from the respective embassy.
In general, good hygiene standards can be maintained 
while on business trips, and business travellers have got a 
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familiar, though variable depending on the country of tra-
vel, infrastructure at their disposal. However, patients in the 
transportation industry, such as trucker, often drive long 
hours, have not got facilities for cooling, and cannot comply 
with short consultation intervals.
In contrast to the aforementioned business trips, private 
trips usually are planned well in advance and in such detail 
that the needs of the patient‘s medical treatment can be ful-
filled. The itinerary, as well as accommodation and means of 
transport, is often planned in detail in advance, and the aver-
age duration of the trip is between a week, or a few weeks. 
Therefore, it is possible to adjust the travel itinerary to the 
course of disease, and its treatment and medication needs. 
Location and climate zone can be selected according to in-
dividual tolerability. A new trend in travelling are adventure 
travels, as well as gap years or sabbaticals for several months, 
comprising ample travel planning across countries. However, 
on occasion, accommodation is chosen spontaneously and on 
the spot. When planning travels of this type, different climatic 
conditions and standards of hygiene have to be considered. 
Furthermore, adequate medical care for the patient is not a 
matter of course in all of the countries which are the destina-
tions of adventure trips. The popularity of travels according 
to the principle “the journey is the reward” is also growing. 
This type of travel can be as diverse as a luxury cruise on a 
cruise liner with high standards in medicine and hygiene, or 
an individual journey with in some cases limited equipment 
and accessibility of facilities, such as cruises on a sailing boat. 
Therefore, the options for a therapy adjusted to the characteri-
stics of the intended trip have to be discussed with the patient.
Variety of systemic drugs for moderate 
to severe psoriasis
The advantage of classical oral drugs for treatment of pso-
riasis, such as ciclosporin, fumarate/dimethyl fumarate, and 
acitretin, is that they are of tablet formulation and, therefore, 
are easy for the patient to carry, do not require cooling and 
can be taken along in large amounts for longer journeys. The 
medical appointments needed for safe treatment are mana-
geable with intervals of four to up to twelve weeks, subject 
to good adjustment to the treatment (Table 1). Based on our 
experience, we recommend regular controls for a decrease in 
side-effects and a detection of side-effects at an early stage, 
although prescribing information allow a more flexible sche-
dule of laboratory controls [5].
Carrying orally administered cortisone preparations, as 
well as classical NSAIDs or COX-2 inhibitors as so-called 
short-term rescue therapy to avoid arthritic relapses is also 
practicable. Given that the product information for apremi-
last and some biologics does not demand fixed laboratory 
controls, the listed recommendations are based on guidelines. 
Doctor’s visits need to be adjusted individually and thus may 
recommend more frequent controls for some patients.
Methotrexate (MTX) can be administered both as 
tablets or by syringe/pen. The preferred application in a 
domestic environment is subcutaneous rather than oral ad-
ministration, providing a better bioavailability of MTX by 
the former method. Oral administration results in variable 
bioavailability, influencing the efficacy of the drug [8]. For 
travel purposes, temporary change from subcutaneous to 
oral administration may be temporarily considered. Howe-
ver, storage and transport options for MTX syringes are 
unsophisticated, as syringes may be stored at room tem-
perature according to the product information. Similar to 
classical therapeutics, the phosphodiesterase inhibitor apre-
milast is administered in tablet form ulation. Therefore, it 
does not demand special transport and storage facilities and 
and is well suited for travelling.
However, treatment with protein-based drugs is different 
from the aforementioned. Systemic therapy for patients with 
moderate to severe psoriasis has been revolutionized by the 
biologics currently available from the group of TNFα and in-
terleukin inhibitors. In compliance with guidelines, affected 
patients would receive regimens with biologics routinely [6]. 
Antibodies demand meticulous storage and cooling, thus in-
volving detailed planning of transfer times. Pharmaceutical 
manufacturers have provided varying instructions for stora-
ge of these drugs. Based on the product information, some 
biologics may be stored a few days (Taltz® [ixekizumab] up 
to 5 days) and in some cases up to two weeks (Humira® [ada-
limumab]) at temperatures of up to 25°C (ixekizumab up 
to 30°C). Other biologics have an absolute need for cooled 
storage (Stelara® [ustekinumab]). Furthermore, the informa-
tion of the original product is not transferable to biosimilars. 
For adalimumab, statements on the non-refrigerated lifeti-
me for biosimilars range from 14 days (Amgevita®, Hulio®, 
Hyrimoz®) to 28 days (Imraldi®) (Table 2). The stability of 
biologics is ensured by various additives that keep the antibo-
dies in solution and buffer them to stabilise the active protein 
structure. Accordingly, we recommend for all biologics and 
biosimilars constant storage in a refrigerator at 2–8°C or in a 
transport box with cooling packs. Many companies and phar-
macies already offer a cooling box upon request. However, 
transport temperatures in the cooling box are not guaranteed, 
and only a few suppliers provide detailed information on the 
timeframe within which sufficient cooling can be guaranteed 
under defined environmental conditions [9, 10].
When travelling by train, bus, car, or plane, transfer 
times and variations have to be taken into account. Given 
that cooling boxes cannot ensure cooling for trips lasting se-
veral hours, connection to the electrical system of the vehicle 
































































Table 1 Routine laboratory controls under systemic therapy [6].
Laboratory parameter Before therapy start After 
4 weeks
After 8 weeks After 
12 weeks
Then every 3 months
Acitretin Blood counts, liver and kidney 
function, serum lipids
X X X X X
Pregnancy test X Continuously, every 4 weeks
Fasting blood glucose X Initially, more frequent controls
Ciclosporin Blood counts, liver and kidney 
function
X X X X X
Uric acid X X X




Blood counts, liver and kidney 
function, serum lipids
X X X X Fumarate continuously 
every 4 weeksb, dimethyl 
fumarate every 3 monthsb
Methotrexate Blood counts, liver and kidney 
function








Blood counts, liver and kidney 
function
X X For therapy with infliximab, labora-
tory controls recommended before 
each administration, every 8 weeks
X X
Hepatitis serology X
Pregnancy testa Recommended [6], since then 
extended approval of ada-
limumab and certolizumab 
pegol during pregnancy
HIV serology Xa
Apremilastc Blood counts, liver and kidney 
function [6]
X X X X
Pregnancy test X
aIndividual therapeutic decision; baccording to product information; caccording to product information, currently no uniform laboratory controls required during therapy 
with biologics. Regular examinations are, however, recommended by the guideline group. Depending on clinical situation, fewer or additional interventions/laboratory tests 
may be required. These must be selected individually for each patient.
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opportunity to store drugs (in small amounts) in the onboard 
refrigerator. However, this matter should be discussed with 
the respective airline prior to the flight.
Administration intervals of drugs
Orally administered and systemically acting drugs are 
usually taken in a self-reliant manner either daily or weekly. 
Administration, therefore, is controlled and managed by 
the patient. Given the short half-times, dosages of MTX, 
ciclosporin, fumarate/dimethyl fumarate, or corticoids are 
rapidly adjustable to the corresponding inflammatory acti-
vity of the disease. We do not initiate a dose-increase phase 
(for example, for fumarates or apremilast) during a schedu-
led journey. This applies in particular to dimethyl fumarate 
with its frequent gastrointestinal side effects.
As to the biologics, the situation is different due to their 
considerable range in administration intervals and half-lifes 
(Figure 1). As for interleukin-23 blockers in particular, injec-
tion intervals can be adjusted by a few days, due to their large 
intervals between individual applications, if there is sufficient 
prior notice and information on a stipulated journey. Thus, 
concerns about transport, cooling, and storage of the drug 
during the trip can be eliminated. In addition, a single ex-
tension of an interval by 1–2 weeks, with otherwise regular 
intervals of 8–12 weeks, is usually well tolerated, and in our 
experience does not lead to loss of efficacy of the drug. A 
longer injection interval will relieve employed persons with 
frequent unplanned travel activities.
Table 2 Lifetime and storage of biologics and biosimilars, 
using adalimumab as an example, according to product 
information in Europe.
Brand name of 
adalimumab
Lifetime of prefilled syringe/
pen according to product infor-




2 years at 2–8°C; only prior to 
use, syringes/pens may be stored 
for up to 14 days at a maximum 
temperature of 25°C
Hyrimoz® 30 months at 2–8°C; only prior to 
use, syringes/pens may be stored 
for up to 14 days at a maximum 
temperature of 25°C
Imraldi® 3 years at 2–8°C; only prior to 
use, syringes/pens may be stored 
for up to 28 days at a maximum 
temperature of 25°C
Customs regulations for systemic drugs
For travel by air, the check-in of syringes and pens as hold 
luggage is not recommended, given that the climatic con-
ditions are not guaranteed in the luggage compartment of 
the aircraft. For transport in carry-on luggage, the traveler 
should obtain a so-called travel letter or doctor’s note that in-
cludes the substance declaration and a short medical urgency 
declaration. This should be issued in English at least, possib-
ly in the respective language of the destination, as well, and 
should contain the name of the prescribing physician/medical 
contact person for the medication (Figure 2). Even if the pa-
tient has a tablet formulation, a declaration may be advisable 
during a  potential security check to certify that the drug is 
required for personal use and is not a prohibited substance.
Travel considerations on location
For travels with fixed residence in urban areas, the storage of 
drugs requiring refrigeration usually is unsophisticated, given 
the availability of a minibar or refrigerator. Even in this case, 
however, protection of the medication against unauthorized 
access (public refrigerator) and a constant temperature have 
to be ensured. At no time should the liquid in the syringe be 
allowed to freeze, as freezing may affect the stability of the 
protein, thus precluding its administration [11–14]. The ori-
ginal container of the medication should be kept at all times, 
and a suitable storage location should be requested at the tra-
vel agency or hotel prior to the journey. In case of round trips 
or travels to rural areas with uncertain infrastructure, the 
mode of administration has to be discussed with the patient 
before departure and, if possible, replacements with an oral 
alternative should be planned well in advance. In countries 
with low standards of hygiene, sufficient amounts of swabs, 
plasters and disinfection spray should be included in the lug-
gage, as availability on location may be limited.
With respect to the disposal of syringes, it is advisable 
to inform the respective cleaning staff about the administ-
ration in order to avoid unpleasant situations and accidental 
punctures. Some pharmaceutical manufacturers offer small 
disposal containers that the patient can order directly from 
the company. However, most injection systems and prefilled 
syringes are provided with sharps injury prevention features, 
thus minimizing the risk of accidental puncture.
Climatic and medical conditions in 
various countries of travel
Patients with psoriasis usually choose warm and dry clima-
te zones for holiday trips (Dead Sea, Mediterranean region, 
Pacific Islands). They have experienced the positive effect of 
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light and brine in balneophototherapy or have been informed 
about it through patient platforms and the media [15–17]. 
However, even in climate zones with sunny, warm, and hu-
mid conditions exacerbations of psoriasis in form of parado-
xical photoaggravation may occur [18]. Especially with the 
additional application of topical, occluding ointments during 
systemic therapy may result in dysbalance of the epidermal 
barrier functions, already impaired by the disease [19]. Even 
after good adjustment of systemic therapies, side effects or 
paradoxical reactions may occur later in the course of the 
disease regardless of travelling [20]. Basic care should be less 
occlusive with higher humidity and temperature; we recom-
mend creams and lotions without oily ingredients. Applica-
tion and expected effects of any topical medication carried 
along should be discussed with the patient. Under extreme 
conditions, for example a trekking tour through the Sahara 
or an expedition in the Amazon region, the selection of suita-
ble clothing is as important as the selection of medication for 
the trip. In rural areas, it should be assumed that no speciali-
zed medical care will be available in case of disease exacerba-
tion. Patients should be furnished with explanatory informa-
tion, they can produce should a case of emergency arise. This 
information should be in English or, ideally, in the respective 
language of destination, and should contain references to the 
disease, as well as information on the non-infectious nature 
of the skin condition, and suitable medication for treatment. 
In addition to the information provided by tour operators, 
patients can nowadays find helpful links through common 
web portals and patients of all age groups have access to 
digital resources [21].
When travelling to a world metropolis, the availability of 
modern medical care may be assumed. However, insurance 
and financial aspects of medical care in countries of travel 
need to be settled in advance. If necessary, the travel health 
insurance coverage should be updated.
It is advisable to supplement the regular travel first-
aid kit containing antiallergics, disinfectants, wound care 
products and anti-infectives with some drugs to alleviate 
potential side effects of systemic therapy. Examples inclu-
de antidiarrheal agents against gastrointestinal symptoms 
of fumarate therapy, proton-pump inhibitors for cortisone 
therapy, and phytotherapeutics for dyspeptic symptoms. 
Certainly, we only recommend taking medication known by 
the patient and tolerated well up to the time of travel to avoid 
being confronted with new side effects in remote regions.
Prevention of country-specific diseases – 
travel vaccinations
In every country, there are specific destination-dependent 
risks of infection. Before departure, the patient should, th-
erefore, consult an agency with expertise in travel/tropical 
medicine to assess the risks in relation to their disease. This 
consultation should include universal, general medical risks. 
As both chronic disease and systemic therapy may increase 
Figure 1 Half-lifes of systemic 
therapeutics for psoriasis.
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the likelihood for infections, especially of the upper respira-
tory tract, a individual consultation regarding the disease is 
also recommended [22, 23]. Susceptibility to infection may 
vary depending on the drug group. Thus, based on current 
knowledge and according to our own experience it can be 
stated that patients treated with interleukin-17 or inter-
leukin-23 inhibitors are less prone to infections of the res-
piratory tract than those treated with TNFα inhibitors (in 
particular adalimumab and infliximab) [24]. Infections that 
can be avoided by vaccinations must be considered individu-
ally for each country of destination.
Some infections transmitted by vectors such as malaria 
and dengue cannot (yet) be prevented by vaccination [25]. 
Accordingly, all travelers should be advised to use effective 
mosquito protection. The risk of mosquito bites should be 
reduced by bringing along sufficient quantities of effective re-
pellents and impregnated clothing. In this regard, the patient 
should be advised to prepare his or her trip conscientiously 
and in good time. Medical information about travel destina-
tions is provided, for example, on the internet pages of the 
German Federal Foreign Office and the Bernhard Nocht In-
stitute for Tropical Medicine (BNIMT) [26, 27]. Consulting 
Figure 2 Travel letter.
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a physician specialized in travel medicine as to whether the 
trip will lead through a malaria region and whether medi-
cinal prophylaxis is indicated in addition to good mosquito 
protection, is also recommended. In this context, potential 
drug-drug interactions should be considered [28].
In general, sufficient vaccination according to current 
guidelines has to be ensured before initiating immunomo-
dulatory systemic medication [23, 29]. This includes both 
basic immunizations, as well as recommended booster vac-
cinations. For some diseases, such as measles, vaccination 
coverage of the population and accordingly of our patients 
is insufficient. In Germany, this led to the introduction of 
the new Measles Protection Act on March 01, 2020 [30]. 
The ECDC (European Center for Disease Prevention and 
Control) illustrates the international prevalence of measles 
[31]. Vaccination gaps should be closed in due time before 
initiating the systemic therapy, and vaccinations should be 
documented [32]. This applies in particular to live vaccina-
tions such as measles/mumps/rubella, varicella and yellow 
fever, the administration of which may be contraindicated 
after initiating immunosuppressive systemic therapy or com-
plicated by mandatory time intervals [23, 33]. Recommenda-
tions require a four-week interval after live vaccination befo-
re initiating immunosuppressive systemic therapy. Once the 
systemic therapy has started, the required interval between 
the last therapeutic dosage and administration of the live vac-
cine is dependent on the respective therapeutic agent and its 
half-life. For example, after administration of the biologic 
etanercept (TNFα inhibitor with a short half-life of 3 days), 
an interval of at least two months before administration of 
a live vaccine is recommended [23], while at least 21 weeks 
are recommended for risankizumab (interleukin-23 inhibitor 
with a long half-life of 29 days) (Figure 1). Here, manufac-
turer information sheets for the various products vary from 
general exclusion of live vaccination to specification of re-
commended intervals after which live vaccination is feasible 
(Table 3).
According to expert consensus, patients should not be 
immunized with live vaccines during ongoing therapy with 
immunosuppressants for treating autoimmune diseases or 
other chronic diseases, due to the risk of disease and severe 
to fatal complications posed by attenuated viruses [35–37]. 
Exceptions may only be possible in justified individual cases 
after risk-benefit assessment [23].
Due to insufficient global vaccination coverage, cases 
of measles have risen dramatically in number in Europe and 
worldwide [38, 39]. This has significantly increased the risk 
of an infection with measles for each individual. Given that 
travelling may pose an increased risk of infection, the me-
dical travel consultation should always comprise serological 
verification of the vaccination status for measles and the pro-
tection against measles, respectively.
Inactivated vaccines (against diphtheria/tetanus/pertus-
sis/polio, hepatitis A, hepatitis B, rabies) can be administered 
without safety concerns in cases of existing inflammatory 
chronic autoinflammatory disease, even under immunomo-
dulatory systemic therapy [40, 41]. In particular for patients 
on immunomodulation, annual influenza vaccination, pneu-
mococcal vaccination (recommended as sequential vaccinati-
on with the 13-valent conjugate vaccine [PCV13] Prevenar®, 
followed by the 23-valent polysaccharide vaccine [PPSV23, 
Pneumovax®] after 6–12 months), and vaccination against 
herpes zoster (inactivated vaccine Shingrix®) should be kept 
in mind [23, 42, 43]. While on immunosuppression, vaccines 
used for primary vaccination (for example hepatitis A vacci-
nation before travelling) may result in an attenuated immu-
ne response [44, 45]. For these so-called neoantigens, sero-
logical verification of vaccination success 4–6 weeks after 
application is recommended, provided there is a serological 
correlate of protection [46]. The validation of successful im-
munization (and additional vaccinations, as required) should 
be considered at the planning stage before the travel.
Ideally, the medical travel consultation should take place 
before final booking and approximately 3–6 months before 
the scheduled departure [47]. If live vaccination is required, it 
may then be possible to interrupt the immunosuppression or 
plan other interventions, if necessary. In certain cases, it may 
not be possible to travel to yellow fever areas. Active and suf-
ficient immunization should be verified after previously per-
formed, single vaccinations. If a vaccination against yellow 
fever is required, the German Standing Committee on Vac-
cination (Ständige Impfkommission, STIKO) recommends a 
second vaccination against yellow fever, if sufficient immune 
response cannot be assumed after primary vaccination. This 
applies to children with primary vaccination at the age of 
up to two years, pregnant women, or individuals vaccinated 
against yellow fever and measles at the same time [48].
There is no need to maintain, for safety reasons, a specific 
interval between administration of an inactivated vaccine and 
an immunosuppressive medication. In our opinion, however, 
immunosuppressive therapy should ideally only start four 
weeks after administration of an inactivated vaccine to en-
sure a sufficient immune response. There are insufficient data 
on the optimal time for administration of an inactivated vac-
cine during ongoing systemic therapy. According to expert 
opinion, the aim should be the largest possible time interval 
between inactivated vaccine and biologic. The situation is dif-
ferent for some drugs utilized in oncology or rheumatology 
that act via B-cell depletion (for example, rituximab). After 
administration of such drugs, a long-lasting, severely impai-
red humoral immune response to vaccines (presumably ac-
companied with reduced efficacy of the vaccination) is to be 
expected. However, also in this case there are no safety risks 
regarding administration of an inactivated vaccine.
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Table 3 Instructions for use and product information regarding live vaccinations under systemic therapy in Europe.
Drug Product information of manufacturer 
about live vaccinations during 
systemic therapy
Recommendations according to STIKO 2019 [23]
Methotrexate No live vaccinations during therapy. According to expert consensus, methotrexate at low dose 
≤ 20 mg/week is no contraindication for MMR, MMR-V, 
and varicella vaccination with Priorix®, PriorixTetra®, or 
Varilrix®; however, individual decision and off-label use. 
Contraindication during high-dose therapy, at least inter-
vals of 4 weeks after vaccination and of 2 months before 
vaccination.
Ciclosporin Vaccination with live vaccines should be 
avoided.
According to expert consensus, ciclosporin at low dose 
≤ 2.5 mg/kg/d is no contraindication for MMR, MMR-V, and 
varicella vaccination with Priorix®, PriorixTetra®, or Varilrix®; 
however, individual decision and off-label use. Contraindi-
cated in case of high-dose therapy.
Dimethyl fumarate No contraindication for live vaccination. Recommendation to administer live vaccines only in 
exceptional cases after individual consideration. Contrain-
dication in case of pronounced lymphopenia.
Apremilast No contraindication for live vaccina-
tions.
Recommendation to complete live vaccinations 4 weeks 
before therapy start or to administer vaccines only after 
individual risk-benefit assessment.
Adalimumab No live vaccinations during therapy. 
For infants exposed to adalimumab in 
utero, vaccination with live vaccines at 
the earliest after 5 months.
Contraindicated during ongoing therapy. Live vaccina-
tion at least 4 weeks before next dose and at the earliest 
2 months after last dose. Vaccination of infants at the ear-
liest 5 months after last exposure during pregnancy.
Etanercept No live vaccinations during therapy. Contraindicated during ongoing therapy. Live vaccina-
tion at least 4 weeks before next dose and at the earliest 
2 months after last dose (in case of clinical remission already 
after 1 month). Vaccination of infants at the earliest 16 weeks 
after last exposure during pregnancy.
Certolizumab pegol No live vaccinations during therapy. Contraindicated during ongoing therapy. Live vaccina-
tion at least 4 weeks before next dose and at the earliest 
2 months after last dose. Vaccination of infants at the ear-
liest 5 months after last exposure during pregnancy.
Golimumab No live vaccinations during therapy. Contraindicated during ongoing therapy. Live vaccina-
tion at least 4 weeks before next dose and at the earliest 
3 months after last dose. Vaccination of infants at the ear-
liest 6 months after last exposure during pregnancy.
Infliximab No live vaccinations during therapy. Contraindicated during ongoing therapy. Live vaccina-
tion at least 4 weeks before next dose and at the earliest 
3 months after last dose. Vaccination of infants at the ear-
liest 6 months after birth.
Ustekinumab No live vaccinations during therapy. Be-
fore vaccination with live vaccine at least 
interval of 15 weeks to last dose of uste-
kinumab, and next dose at the earliest 
2 weeks after vaccination.
Contraindicated during ongoing therapy. Live vaccina-
tion at least 2 weeks before next dose and at the earliest 
15 weeks after last therapeutic dose.
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Conclusion
Before departure, the patient should be advised about in-
fection risks at the destination and during travelling. Travel 
consultation by a specialized center for travel or tropical me-
dicine is recommended, and adequate vaccination is essential. 
Depending on the conditions of travelling, systemic therapy 
can be adjusted in advance as concerns both, dosage form and 
administration intervals. A careful selection, by the patient, of 
the desired destination in terms of infection risk and stress due 
to climate and local customs while travelling would be ideal.
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Drug information referred to 
November 15, 2019
Kyntheum® 210 mg injection solution in prefilled syringe: 
Leo Pharma GmbH, Cosentyx® 150 mg injection solution 
in prefilled syringe: Novartis Pharma GmbH, Taltz® 80 mg 
injection solution in prefilled syringe: Lilly Deutschland 
GmbH, Skyrizi® 75 mg injection solution in prefilled syringe: 
AbbVie Deutschland GmbH & Co. KG, Ilumetri® 100 mg 
injection solution in prefilled syringe: Almirall Hermal 
GmbH, Stelara® 90 mg injection solution in prefilled syrin-
ge: Janssen-Cilag GmbH, Xeljanz® 5 mg film-coated tablets: 
Pfizer Pharma GmbH, Simponi® 50 mg injection solution in 
prefilled syringe: MSD Sharp & Dohme GmbH, Amgevita® 
40 mg injection solution in prefilled syringe: Amgen GmbH, 
Imraldi® 40 mg injection solution in prefilled syringe: Sam-
sung Bioepis, Cimzia® 200 mg injection solution in prefilled 
Drug Product information of manufacturer 
about live vaccinations during 
systemic therapy
Recommendations according to STIKO 2019 [23]
Guselkumab No live vaccinations during therapy. 
Before vaccination with live vaccine at 
least interval of 12 weeks to last dose, 
and next dose at the earliest 2 weeks 
after vaccination.
No specific referencea
Tildrakizumab No live vaccinations during therapy. 
Wait at least 4 weeks after vaccination 
before initiating treatment with tildraki-
zumab. During and for at least 17 weeks 
after treatment with Ilumetri®, patients 
should not receive live vaccines.
No specific referencea
Risankizumab No live vaccinations during therapy. No 
live vaccination for at least 4 weeks be-
fore start of therapy, during treatment 
and for at least 21 weeks after treatment.
No specific referencea
Brodalumab Live vaccines should not be given 
concomitantly.
No specific referencea
Secukinumab Live vaccines should not be given 
during therapy.
Contraindication during ongoing therapy. Vaccination at 
the earliest 2 months after last dose and at least interval of 
4 weeks before next dose.
Ixekizumab Ixekizumab should not be given conco-
mitantly to live vaccines.
No specific referencea
aIn general, for the majority of biologics insufficient data are available on evaluation of efficacy and risk of live vaccination during 
ongoing therapy. Accordingly, based on international expert consensus and current STIKO recommendation, live vaccination 
during therapy with these biologics is contraindicated [23]. For some biologics in low-dose setting, however, vaccination with the 
MMR and varicella vaccines Priorix®, PriorixTetra®, or Varilrix® may be considered after individual risk-benefit assessment [23]: This 
is, however, not recommended by the current version of the S2k guideline on therapy of psoriasis in children and adolescents [34].
Table 3 Continued.
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syringe: UCB Pharma GmbH, Humira® 40 mg injection so-
lution in prefilled syringe: AbbVie Deutschland GmbH & Co 
KG, Enbrel® 50 mg injection solution in prefilled syringe: 
Pfizer Pharma GmbH, Otezla® 10/20/30 mg film-coated tab-
lets: Celgene GmbH, Skilarence® 30 mg film-coated tablets: 
Almirall Hermal GmbH, Neotigason® 25 mg hard capsu-
les: Puren Pharma GmbH & Co KG, Sandimmun® Opto-
ral 100 mg soft capsules: Novartis Pharma GmbH, metex® 
50 mg/ml injection solution, prefilled syringe 10 mg: medac 
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